«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中国美容医学》[ISSN:1008-6445/CN:61-1347/R]

卷:

期数:

2021年1期

页码:

49-53

栏目:

出版日期:

2021-01-10

文章信息/Info

Title:

Efficacy Evaluation of Cynergy Dual-wavelength Laser Combined with Timolol
Maleate in the Treatment of Superficial Infantile Hemangioma

文章编号:

1008-6455（2021）01-0049-04

作者:

 何洛芸; 韦妮波; 马 瑗; 王建辉

Author(s):

 HE Luo-yun; WEI Ni-bo; MA Yuan; WANG Jian-hui

关键词:

 [关键词]Cynergy双波长激光; 马来酸噻吗洛尔; 血管瘤; 视觉模拟评分; 不良反应

Keywords:

 Key words:cynergy dual wavelength laser; timolol maleate;  hemangioma; visual simulation score;  adverse reaction

分类号:

R732.2

文献标志码:

A

摘要:

[摘要]目的：观察Cynergy双波长激光联合马来酸噻吗洛尔治疗婴儿浅表性血管瘤的疗效。方法：回顾性分析2016年1
月-2018年10月于笔者医院接受Cynergy双波长激光联合马来酸噻吗洛尔治疗的208例婴儿浅表性血管瘤患儿资料，其中女
婴159例，男婴49例，平均年龄为（3.9±0.8）个月，Cynergy双波长治疗间隔为5周，马来酸噻吗洛尔溶液每天外敷2次，
每次30min，分别于治疗后的5、15、25和35周采用视觉模拟评分（VAS）进行疗效评价，记录不良反应，分析不同厚度和
面积血管瘤的VAS评分、治疗时间和治疗次数。结果：208例患儿经过5～35周治疗后，均得到不同程度的改善，其中195
例婴儿完全治愈，治愈率为93.75%，治疗后的5、15、25和35周VAS评分分别为(3.13±0.21)分、（4.47±0.49）分、
（5.47±0.69）分和（7.78±1.14）分，随着治疗时间的增加，VAS评分逐渐增加；不同时间点不同厚度血管瘤组VAS评
分存在统计学意义（F 组间=167.287，P ＜0.05；F 时间=89.281，P ＜0.05；F 组间×时间=103.545，P ＜0.05），其中55例厚度＜1mm
组的患儿VAS评分更高，治疗5周时VAS评分为（7.36±1.12）分，治疗第15周时VAS评分明显增加，其中44例（80.0%）患儿
完全消退，第25周时，所有患儿的VAS评分均为10分，血管瘤完全消退；不同时间点不同面积血管瘤组VAS评分存在统计学意
义（F 组间=153.219，P ＜0.05；F 时间=94.317，P ＜0.05；F 组间×时间=112.932，P ＜0.05），不同面积血管瘤组治疗时间和治疗次
数存在统计学差异（P ＜0.05），其中＜3cm2组治疗时间最短，治疗次数最少；不良反应轻微，未出现心血管、呼吸系统以
及眼部等不良反应。 结论：Cynergy双波长激光联合马来酸噻吗洛尔治疗婴儿浅表性血管瘤效果显著，安全性高。

Abstract:

Abstract:Objective To observe the therapeutic effect of Cynergy dual wavelength laser combined with timolol maleate on
superficial infantile hemangioma. Methods 208 infants with superficial hemangioma who received Cynergy dual-wavelength
laser combined with timolol maleate from January 2016 to October 2018 were retrospectively analyzed, including 159 female
infants and 49 male infants with an average age of 3.9±0.8 months. Cynergy dual-wavelength treatment interval was 5 weeks.
timolol maleate solution was externally applied twice a day for 30min each time. Visual analogue scale (VAS) was used to
evaluate the therapeutic effect at 5, 15, 25 and 35 weeks after treatment respectively. Adverse reactions were recorded and VAS
scores, treatment time and treatment times of hemangiomas of different thickness and area were analyzed. Results 208 infants
were improved in different degrees after 5-35 weeks of treatment. 195 infants were completely cured with a cure rate of 93.75%.
VAS scores at 5, 15, 25 and 35 weeks after treatment were 3.13±0.21, 4.47±0.49, 5.47±0.69 and 7.78±1.14 respectively. VAS scores
gradually increased with the increase of treatment time. VAS scores of hemangioma groups with different thickness at different
time points were statistically significant (F group =167.287, P ＜0.05, F time=89.281,P ＜0.05, F group×time =103.545, P ＜0.05). among
them, the VAS score of 55 infants in the group with thickness ＜1mm was higher, the VAS score was 7.36±1.12 at the 5th
week of treatment, and the VAS significantly increased at the 15th week of treatment, 44 infants (80.0%) completely subsided,
and at the 25th week, all infants had VAS scores of 10 points, and hemangioma completely subsided. VAS scores of hemangioma
groups with different areas and different time points were statistically significant (F group =153.219, P ＜0.05, F time =94.317, P ＜0.05,
F group×time=112.932, P ＜0.05). the treatment time and treatment times of hemangioma groups with different areas were
statistically different (P ＜0.05), of which＜3 cm2 group had the shortest treatment time and the least treatment times.
Adverse reactions were mild and no adverse reactions such as cardiovascular, respiratory and eye reactions occurred.
Conclusion Cynergy dual wavelength laser combined with timolol maleate is effective and safe in the treatment of
superficial hemangioma.

常用功能

更新日期/Last Update: 2021-02-02